Summary
Harringtonine and its derivative homoharringtonine are ester-containing anti-leukemic alkaloids isolated from the tree Cephalotaxus harringtonia. In order to compare their antitumor activity against solid tumors, in vitro culture of fresh tumor cells from 23 patients was carried out with a soft agar assay system. Tumor cells were exposed to 0.001–1.0 μg/ml of each agent for either 1 h prior to plating or by continuous exposure. Significant antitumor activity was noted for harringtonine in ovarian and endometrial carcinoma at the 0.01 μg/ml concentration. In the continuous exposure studies, homoharringtonine proved to be more potent than harringtonine. Significant antitumor activity of homoharringtonine was noted in sarcoma and breast cancer as well as in ovarian and endometrial carcinoma. In the continuous exposure studies the mean area under the survival-concentration curve was significantly less for homoharringtonine than for harring-tonine 5.04±3.87 and 6.15±3.46, respectively (p<0.005). The ratio of mean ID50 (harringtonine/ homoharringtonine) was 5.2. However, there was no significant difference between those two agents with a 1 h exposure. Our results suggest that homoharringtonine and harringtonine may be of use in selected solid tumors, and that homoharringtonine has a greater degree of colony inhibition with continuous exposure.
Similar content being viewed by others
References
Department of Pharmacology, Institute of Materia Medica, Chinese Academy of Medical Sciences: The anti-tumor effects and pharmacologic actions of harringtonine. Chinese Med J 3:131–136, 1977
Powell RG, Weisleder D, Smith CR, Jr: Anti-tumor alkaloids from Cephalotaxus harringtonia: Structure and activity. J Pharm Sci 61:1227–1230, 1972
Chinese People's Liberation Army 187th Hospital: Harring-tonine in acute leukemias: Clinical analysis of 31 cases. Chinese Med J 3:319–324, 1977
Hamburger AW, Salmon SE: Primary bioassay of human tumor stem cells. Science 197:461–463, 1977
Alberts DS, Chen HSG, Soehnlen B, Salmon SE, Surwit ES, Young L, Moon TE: In vitro clonogenic assay for predicting response of ovarian cancer to chemotherapy. Lancet 2:340–343, 1980
Von Hoff DD, Casper J, Bradley E, Jones D, Makuch R: Association between human tumor colony forming assay results and response of an individual patient's tumor to chemotherapy. Am J Med 70:1027–1032, 1981
Salmon SE, Liu RH, Casazza AM: Evaluation of new anthracycline analogs with the human tumor stem cell assay. Cancer Chemother. Pharmacol 6:103–110, 1981
Jiang TL, Salmon SE, Liu RH: Activity of camptothecin, harringtonine, cantharidin and curcumae in the human tumor stem cell assay. Eur J Cancer (in press).
Clinical Brochure of Homoharringtonine (NSC 141633). July 1981. Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment, NCI
Soehnlen B, Young L, Liu RH: Standard laboratory procedures for in vitro assay of human tumor stem cells. In Salmon SE (ed): Cloning of Human Tumor Stem Cells. A.R. Liss & Co., New York, 1980, pp 331–338
Salmon SE, Meyskens FL, Jr, Alberts DS, Soehnlen B, Young L: New drugs in ovarian cancer and malignant melanoma: In vitro Phase II screening with the human tumor stem cell assay. Cancer Treat Rep 65:1–12, 1981
Von Hoff DD, Coltman CA, Jr, Forseth B: Activity of 9–10 anthracene-dicarboxaldehyde bis [(4,5-dihydro-1 H-imidazol-2-yl)hydrazone] dihydro-chloride (CL 216, 942) in a human tumor cloning system. Leads for Phase II trials in man. Cancer Chemother Pharmacol 6:141–144, 1981
Author information
Authors and Affiliations
Additional information
Visiting scholar, Institute of Chinese Materia Medica, The Academy of Traditional Chinese Medicine, Beijing, China.
Rights and permissions
About this article
Cite this article
Jiang, T.L., Liu, R.H. & Salmon, S.E. Comparative in vitro antitumor activity of homoharringtonine and harringtonine against clonogenic human tumor cells. Invest New Drugs 1, 21–25 (1983). https://doi.org/10.1007/BF00180188
Issue Date:
DOI: https://doi.org/10.1007/BF00180188